Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Beyondspring Inc (NQ: BYSI)
16.37 USD  +0.05 (+0.31%)
Streaming Delayed Price  /  Updated: 11:10 AM EDT, Aug 23, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 1,855
Open 16.32
Bid (Size) 16.37 (3)
Ask (Size) 16.69 (2)
Prev. Close 16.32
Today's Range 16.32 - 16.97
52wk Range 13.06 - 26.98
Shares Outstanding 16,879,628
Dividend Yield N/A
Performance
YTD
-11.70%
-11.70%
1 Month
+0.99%
+0.99%
3 Month
+12.90%
+12.90%
6 Month
-10.23%
-10.23%
1 Year
-27.08%
-27.08%
Top News
More News
BeyondSpring’s Plinabulin Demonstrates Superior Quality of Life Over Pegfilgrastim in a Head-to-Head Comparison Trial for the Prevention of Neutropenia
Data to be Presented at IASLC 2019 World Conference on Lung Cancer Read More
from GlobeNewswire News Releases
BeyondSpring Announces Pricing of Public Offering of Ordinary Shares
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology... Read More
from GlobeNewswire News Releases
More News
Read More
BeyondSpring Announces Proposed Public Offering of Ordinary Shares
from GlobeNewswire News Releases
BeyondSpring Provides Operational Update and First Quarter 2019 Financial Results
from GlobeNewswire News Releases
BeyondSpring Set to Join FTSE Russell 3000® Index
from GlobeNewswire News Releases
BeyondSpring to Present at the Jefferies 2019 Healthcare Conference
from GlobeNewswire News Releases
BeyondSpring Abstract Demonstrating Bone Pain Benefit with Lead Asset, Plinabulin, versus Neulasta for Neutropenia Prevention Presented at ISPOR 2019
from GlobeNewswire News Releases
BeyondSpring’s Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting
from GlobeNewswire News Releases
BeyondSpring’s Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting
from GlobeNewswire News Releases
Recent Analysis Shows Moelis, BeyondSpring, Village Super Market, and Biofrontera AG Sponsored ADR Market Influences — Renewed Outlook, Key Drivers of Growth
from GlobeNewswire News Releases
BeyondSpring Files 2018 Annual Report on Form 20-F
from GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.